Immunogenicity and Efficacy in<i>Aotus</i>Monkeys of Four Recombinant<i>Plasmodium falciparum</i>Vaccines in Multiple Adjuvant Formulations Based on the 19-Kilodalton C Terminus of Merozoite Surface Protein 1

DOI Web Site 被引用文献1件
  • Sanjai Kumar
    <!--label omitted: 1-->Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland 208921;
  • William Collins
    <!--label omitted: 2-->Division of Parasitic Diseases and Scientific Resources Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 303332;
  • Andrea Egan
    <!--label omitted: 1-->Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland 208921;
  • Anjali Yadava
    <!--label omitted: 1-->Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland 208921;
  • Olivier Garraud
    <!--label omitted: 1-->Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland 208921;
  • Michael J. Blackman
    <!--label omitted: 3-->Division of Parasitology, National Institute for Medical Research, London NW71AA, United Kingdom3;
  • Jose A. Guevara Patino
    <!--label omitted: 3-->Division of Parasitology, National Institute for Medical Research, London NW71AA, United Kingdom3;
  • Carter Diggs
    <!--label omitted: 4-->Malaria Vaccine Development Program, U.S. Agency for International Development, Washington, D.C. 205234
  • David C. Kaslow
    <!--label omitted: 1-->Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland 208921;
  • J. M. Mansfield
    editor

抄録

<jats:title>ABSTRACT</jats:title><jats:p>The immunogenicity and protective efficacy of four versions of recombinant C-terminal 19-kDa epidermal growth factor-like region of the major surface protein 1 (rMSP1<jats:sub>19</jats:sub>) of<jats:italic>Plasmodium falciparum</jats:italic>was studied in<jats:italic>Aotus</jats:italic>monkeys. Vaccination with each of the four rMSP1<jats:sub>19</jats:sub>constructs elicited high levels of antibodies to MSP1<jats:sub>19</jats:sub>but only one construct, the 19-kDa fragment expressed as a secreted fusion protein from<jats:italic>Saccharomyces cerevisiae</jats:italic>(yP30P2MSP1<jats:sub>19</jats:sub>), induced a high degree of protective immunity in<jats:italic>Aotus nancymai</jats:italic>against lethal<jats:italic>P. falciparum</jats:italic>challenge. Protective formulation required Freund's adjuvant; vaccination with yP30P2MSP1<jats:sub>19</jats:sub>in six other adjuvants that are suitable for human use induced lower levels of antibody response and no protection. These results emphasize the need to continue the search for an adjuvant that is comparable to Freund's adjuvant in potency and is safe for use in humans.</jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ